×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Pemphigus Market Trends

ID: MRFR/Pharma/5024-HCR
100 Pages
Rahul Gotadki
October 2025

Pemphigus Market Research Report Information  By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Pemphigus Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Pemphigus Market

The pemphigus market trends with regards to pemphigus vulgaris, an unusual autoimmune blistering disease that affects the skin and mucous membranes, have experienced significant changes in recent years. Pemphigus comes in several subtypes with pemphigus vulgaris and pemphigus foliaceus being the most common. One major development is the exploration of targeted therapies and biologicals. Traditionally, treatment strategies for pemphigus are rooted in systemic corticosteroids and immunosuppressive agents, but there’s a growing shift towards more specific interventions. Biologics such as rituximab which targets B cells involved in the autoimmune response have shown potential for controlling the disease without heavy reliance on systemic corticosteroids and thus limiting side effects that come along.

The dynamics of market trends within pemphigus are underpinned by advances in diagnosis. The advent of sophisticated immunological and molecular techniques has enhanced diagnostic accuracy and speed allowing clinicians to rapidly distinguish between different subtypes of pemphigus for appropriate initiation of therapy. Early intervention is crucial for management of pemphigus; it helps to prevent further progression of diseases thus improving patient outcomes.

Pemphigus is becoming relevant with telemedicine integration into digital health solutions. Telemedicine allows remote consultations from dermatologists and specialists creating convenience for patients who suffer from this disease. Using digital platforms to monitor progression of disease, track responses to treatment and improve patient education is a way forward towards obtaining paction-oriented care in Pemphigu especially during this COVID-19 pandemic.

Another trend observed within the pemphigus market involves combination therapies. Though corticosteroids remain fundamental agents in treating this condition, recent interest has grown on combinations with other immunomodulatory drugs or biologics designed to offer an improved control over diseases while minimizing undesirable side effects related to high dosage steroids. This trend bears in mind the acute phase of blister formation and underlying autoimmune processes during pemphigus management.

Research and development activities are shaping the pemphigus market in efforts to understand the immunopathogenesis of this condition as well as identify new targets for treatment. Academic institutions, pharmaceutical companies, and research organizations join forces together to explore innovative therapies such as targeted immunotherapies and gene-based interventions that may transform pemphigus care and enhance long-term effectiveness.

Patient advocacy has become increasingly important in the market for pemphigus. By raising awareness, providing resources, and creating a sense of community among those living with the condition, these organizations help individuals affected by pemphigus. Other functions include funding research initiatives while ensuring policies supporting access to novel treatments are being advanced thereby making an environment that paves ways for better support of people suffering from Pemphigus.

Regulatory considerations play an integral role in the pemphigus market as regulatory bodies actively evaluate safety and efficacy of new therapeutic interventions. In order to bring new innovative treatments for Pemphigu on the market more efficiently it is necessary to streamline approval processes by fostering collaboration between regulators, healthcare professionals, and industry stakeholders.

Global collaborations and partnerships have been observed within the pemphigus sector since it is a rare disease; therefore concerted efforts are needed to advance researches about it as well as its treatment options. Healthcare institutions work closely with pharmaceutical firms as well as advocacy groups so that comprehensive approaches can be taken towards addressing challenges associated with Pemphigu leading to collective patient care improvement outcomes.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is Pemphigus?

Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

What is the CAGR of the Pemphigus Market?

The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

What is the major driver for the Pemphigus Market?

The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

Which is the leading regional Pemphigus Market?

Americas are anticipated to dominate the global Pemphigus Market.

What are the leading Pemphigus Market players?

Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

Market Summary

As per MRFR analysis, the Pemphigus Market Size was estimated at 578.9 USD Million in 2024. The Pemphigus industry is projected to grow from 634.1 in 2025 to 1410.37 by 2035, exhibiting a compound annual growth rate (CAGR) of 8.39% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Pemphigus Market is poised for growth driven by innovative therapies and increasing awareness.

  • The emergence of targeted therapies is reshaping treatment paradigms in the Pemphigus Market. North America remains the largest market, while Asia-Pacific is recognized as the fastest-growing region. In the segment analysis, Dermatology holds the largest share, whereas Oncology is experiencing rapid growth. The rising incidence of Pemphigus and advancements in biologic therapies are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 578.9 (USD Million)
2035 Market Size 1410.37 (USD Million)
CAGR (2025 - 2035) 8.39%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://medically.roche.com/global/en/microsites/about-pv/pv-treatment-management.html">Roche</a> (CH), Bristol-Myers Squibb (US), Novartis (CH), Amgen (US), Sanofi (FR), <a href="https://www.merckmanuals.com/professional/dermatologic-disorders/bullous-diseases/pemphigus-vulgaris">Merck &amp; Co</a>. (US), Pfizer (US), GSK (GB), Eli Lilly (US)</p>

Market Trends

The Pemphigus Market is currently experiencing notable developments, driven by advancements in treatment options and increasing awareness of the disease. Pemphigus, an autoimmune disorder characterized by blistering of the skin and mucous membranes, has garnered attention due to its impact on patients' quality of life. The market appears to be evolving as pharmaceutical companies invest in research and development, aiming to introduce innovative therapies that could enhance patient outcomes. Furthermore, the growing prevalence of pemphigus is likely to stimulate demand for effective treatment solutions, thereby shaping the market landscape. In addition, the Pemphigus Market is influenced by the rising incidence of autoimmune diseases globally. This trend suggests a potential increase in the number of patients seeking medical intervention, which may lead to a surge in the development of targeted therapies. Regulatory bodies are also playing a crucial role in facilitating the approval process for new drugs, which could further accelerate market growth. Overall, the Pemphigus Market appears poised for expansion, with a focus on improving treatment modalities and enhancing patient care.

Emergence of Targeted Therapies

The Pemphigus Market is witnessing a shift towards the development of targeted therapies that specifically address the underlying mechanisms of the disease. These innovative treatments aim to minimize side effects while maximizing efficacy, potentially transforming the management of pemphigus.

Increased Patient Awareness

There is a growing awareness among patients regarding pemphigus and its treatment options. This heightened awareness is likely to lead to earlier diagnosis and intervention, which may improve patient outcomes and drive demand for effective therapies in the market.

Regulatory Support for Drug Development

Regulatory agencies are increasingly supportive of the development of new therapies for pemphigus. This trend indicates a favorable environment for pharmaceutical companies, as streamlined approval processes may facilitate the introduction of novel treatments into the market.

Pemphigus Market Market Drivers

Market Growth Projections

The Global Pemphigus Market Industry is projected to experience substantial growth over the coming years. With a market value of 1.67 USD Billion in 2024, it is anticipated to reach 4.0 USD Billion by 2035. This growth trajectory reflects a CAGR of 8.25% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in treatment modalities, and increased research activities. The market's expansion indicates a growing recognition of pemphigus as a significant health concern, necessitating ongoing investment in therapeutic development and patient care.

Rising Incidence of Pemphigus

The Global Pemphigus Market Industry experiences a notable increase in the incidence of pemphigus, an autoimmune blistering disorder. Recent data suggests that the prevalence of pemphigus vulgaris is approximately 0.5 to 3 cases per 100,000 individuals globally. This rising incidence is likely to drive the demand for effective treatment options, contributing to the market's growth. As the population ages and awareness of autoimmune diseases increases, the Global Pemphigus Market Industry is projected to reach 1.67 USD Billion in 2024, indicating a strong need for innovative therapies and management strategies.

Supportive Government Policies

Supportive government policies and initiatives play a pivotal role in the Global Pemphigus Market Industry. Regulatory agencies are increasingly recognizing the need for effective treatments for rare diseases, including pemphigus. Policies that promote research funding, expedite drug approvals, and provide incentives for pharmaceutical companies are likely to foster innovation in this field. Such supportive measures can enhance the availability of treatment options, ultimately benefiting patients. As the market evolves, these policies may contribute to a more robust Global Pemphigus Market Industry, ensuring that patients have access to necessary therapies.

Growing Awareness and Education

Growing awareness and education regarding pemphigus among healthcare professionals and patients contribute positively to the Global Pemphigus Market Industry. Initiatives by health organizations and patient advocacy groups aim to disseminate information about the disease, its symptoms, and treatment options. This increased awareness is likely to facilitate early diagnosis and prompt treatment, thereby improving patient outcomes. As more individuals seek medical attention, the demand for therapies is expected to rise, further propelling the Global Pemphigus Market Industry's growth trajectory.

Advancements in Treatment Modalities

Innovations in treatment modalities significantly influence the Global Pemphigus Market Industry. The introduction of biologics and targeted therapies has transformed the management of pemphigus, offering improved efficacy and safety profiles. For instance, monoclonal antibodies such as rituximab have shown promising results in clinical trials, leading to increased adoption in clinical practice. This trend is expected to continue, with the market projected to expand at a CAGR of 8.25% from 2025 to 2035. As new therapies emerge, the Global Pemphigus Market Industry is likely to witness substantial growth, enhancing patient outcomes and quality of life.

Increased Research and Development Activities

The Global Pemphigus Market Industry benefits from heightened research and development activities aimed at understanding the pathophysiology of pemphigus. Government and academic institutions are increasingly investing in studies to identify novel therapeutic targets and biomarkers. This surge in R&D is anticipated to lead to the discovery of new treatment options, thereby expanding the market. With a projected market value of 4.0 USD Billion by 2035, the emphasis on innovation and scientific exploration is likely to play a crucial role in shaping the future of the Global Pemphigus Market Industry.

Market Segment Insights

By Application: Dermatology (Largest) vs. Oncology (Fastest-Growing)

<p>The Pemphigus Market exhibits a diverse application landscape, predominantly influenced by segments such as <a href="https://www.marketresearchfuture.com/reports/dermatology-drug-market-24347">Dermatology drugs</a> , Oncology, Immunology, and Transplantation. In this competitive arena, Dermatology takes the lead with the largest market share, driven by the rising prevalence of pemphigus diseases. The Oncology segment, while smaller, showcases significant promise as it addresses complications arising from pemphigus in cancer patients and shows a rapidly expanding market presence due to evolving treatment paradigms.</p>

<p>Dermatology (Dominant) vs. Oncology (Emerging)</p>

<p>Dermatology maintains its position as the dominant application in the Pemphigus Market, primarily due to the high incidence and awareness of pemphigus among dermatological conditions. This segment is characterized by a variety of treatment options ranging from systemic therapies to innovative biologics, ensuring comprehensive patient management. Conversely, Oncology is emerging as a vital sector within the market, particularly as research uncovers correlations between pemphigus and cancer. The anticipated growth in this area is fueled by increasing recognition of the need for targeted therapies and integrated treatment approaches in oncological patients, making it a crucial focus for future research and market strategies.</p>

By Type of Pemphigus: Pemphigus Vulgaris (Largest) vs. Pemphigus Foliaceus (Fastest-Growing)

<p>The Pemphigus market is primarily dominated by Pemphigus Vulgaris, which accounts for the largest market share among the different types of pemphigus. This condition is characterized by blister formation and is often considered a more severe form of the disease, thus attracting greater attention and more treatment options. Pemphigus Foliaceus, while smaller in market size, is emerging rapidly due to increasing awareness and diagnosis rates among healthcare providers, making it a focus for future growth and development.</p>

<p>Pemphigus Vulgaris (Dominant) vs. Pemphigus Foliaceus (Emerging)</p>

<p>Pemphigus Vulgaris stands out as the dominant segment in the Pemphigus market due to its prevalence and severity, leading to more significant clinical focus and investment in treatment options. Patients suffering from this condition often require long-term management, which intensifies the demand for therapies. In contrast, Pemphigus Foliaceus is gaining momentum as it is recognized as a less severe but still impactful form of pemphigus. The emerging research into targeted therapies and biological treatments for Pemphigus Foliaceus is driving its rapid growth and leading to an increased number of diagnosed cases, thus expanding its market share.</p>

By Treatment Type: Corticosteroids (Largest) vs. Biologics (Fastest-Growing)

<p>Corticosteroids continue to dominate the Pemphigus treatment landscape due to their effectiveness in rapidly reducing inflammation and controlling symptoms. They hold the largest market share among treatment types, being the first-line therapy prescribed for most patients, leading to consistent utilization rates. Immunosuppressants and plasmapheresis also play vital roles, albeit with lower prevalence compared to corticosteroids and the emerging <a href="https://www.marketresearchfuture.com/reports/biologics-market-1339">biologics </a>segment.</p>

<p>Corticosteroids (Dominant) vs. Biologics (Emerging)</p>

<p>Corticosteroids are established as the dominant choice in the Pemphigus Market, favored for their quick therapeutic action and ability to induce remission in patients. They are often used in conjunction with other agents to prevent flare-ups. In contrast, biologics represent an emerging segment that is gaining traction due to their targeted approach in treating autoimmune disorders like Pemphigus. While biologics are still in the early stages of adoption, their efficacy in reducing disease activity without the broad immunosuppressive effects of traditional therapies makes them appealing and potentially faster-growing in the coming years.</p>

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

<p>In the Pemphigus market, the Route of Administration segment displays a distinct distribution among its three key values: Oral, Intravenous, and Subcutaneous. Oral administration remains the dominant choice among healthcare professionals due to its ease of use and patient compliance. This method accounts for the majority of market share as patients prefer non-invasive routes over more complex delivery mechanisms. On the other hand, Intravenous administration is emerging as the fastest-growing method in this space. Its growth can be attributed to the increasing focus on targeted therapy, which allows for more efficient and rapid administration of treatment. The Subcutaneous route is also significant, though it currently holds a smaller market share compared to the dominant and fastest-growing methods.</p>

<p>Administration Route: Oral (Dominant) vs. Intravenous (Emerging)</p>

<p>The Oral administration route is characterized by its high patient acceptability and ease of use, making it a favored option among physicians when prescribing treatments for Pemphigus. This method allows for straightforward self-administration, which is crucial for patient adherence to treatment regimens. Conversely, Intravenous administration, while less commonly used, is becoming important as an emerging route for more severe cases requiring rapid therapeutic action. This method delivers medication directly into the bloodstream, providing faster and more effective treatment. The growing preference for precision medicine and advancements in drug formulations are driving the increased utilization of both routes in treating Pemphigus.</p>

By Patient Demographics: Adults (Largest) vs. Geriatric (Fastest-Growing)

<p>The Pemphigus Market is significantly influenced by patient demographics, particularly among adults who represent the largest segment within this therapeutic area. This demographic showcases a higher prevalence of pemphigus, contributing substantially to the market share. In contrast, the geriatric population, while smaller in comparison, is showing an increased incidence of pemphigus conditions, leading to a notable share in the market.</p>

<p>Adults (Dominant) vs. Geriatric (Emerging)</p>

<p>Adults presently dominate the Pemphigus Market due to their higher exposure and diagnosis rates. This group is characterized by a greater likelihood of experiencing pemphigus vulgaris, which necessitates targeted treatment strategies. On the other hand, the geriatric segment is emerging rapidly, driven by an aging population that is at higher risk for autoimmune disorders including pemphigus. As healthcare access improves, this demographic is likely to see increased awareness and diagnosis rates, making it an important area for future growth and tailored therapies.</p>

Get more detailed insights about Pemphigus Market Research Report – Forecast to 2035

Regional Insights

North America : Market Leader in Pemphigus

North America is poised to maintain its leadership in the Pemphigus market, holding a significant share of 300.0M in 2025. The region's growth is driven by increasing awareness of autoimmune diseases, advancements in biologics, and supportive regulatory frameworks. The FDA's expedited approval processes for innovative therapies further catalyze market expansion, meeting the rising demand for effective treatments. The competitive landscape is robust, with key players like Roche, Bristol-Myers Squibb, and Amgen leading the charge. The U.S. remains the largest market, supported by a well-established healthcare infrastructure and high R&D investments. The presence of major pharmaceutical companies ensures a steady pipeline of new therapies, enhancing treatment options for patients suffering from Pemphigus.

Europe : Emerging Market Dynamics

Europe is witnessing a growing interest in the Pemphigus market, with a market size of 150.0M in 2025. Factors such as increasing prevalence of autoimmune disorders and enhanced healthcare access are driving demand. Regulatory bodies are actively promoting research and development, with initiatives aimed at expediting the approval of new treatments, thereby fostering a conducive environment for market growth. Leading countries like Germany, France, and the UK are at the forefront, supported by a strong presence of pharmaceutical giants such as Novartis and Sanofi. The competitive landscape is characterized by collaborations and partnerships aimed at innovation. The European Medicines Agency (EMA) is committed to ensuring that patients have access to effective therapies, stating that "the EMA prioritizes the approval of treatments for rare diseases to improve patient outcomes."

Asia-Pacific : Emerging Powerhouse in Healthcare

Asia-Pacific is emerging as a significant player in the Pemphigus market, with a projected size of 100.0M in 2025. The region's growth is fueled by increasing healthcare investments, rising awareness of autoimmune diseases, and a growing patient population. Governments are implementing policies to enhance healthcare access, which is expected to drive demand for Pemphigus treatments in the coming years. Countries like Japan, China, and India are leading the charge, with a mix of local and international players vying for market share. The competitive landscape is evolving, with companies like Amgen and GSK expanding their presence. The region's diverse healthcare systems present both challenges and opportunities for market entrants, as they navigate varying regulatory environments and patient needs.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the Pemphigus market, with a market size of 28.9M in 2025. The growth is driven by increasing healthcare investments and a rising awareness of autoimmune diseases. Governments are focusing on improving healthcare infrastructure, which is expected to enhance access to treatments for Pemphigus patients in the region. Countries like South Africa and the UAE are leading the way, with a growing number of healthcare facilities and initiatives aimed at improving patient care. The competitive landscape is still developing, with opportunities for both local and international players. As the region continues to evolve, the presence of key players will be crucial in addressing the unmet needs of Pemphigus patients.

Key Players and Competitive Insights

The Pemphigus Market is characterized by a dynamic competitive landscape, driven by increasing incidences of autoimmune diseases and a growing demand for innovative therapies. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Novartis (CH) are strategically positioned to leverage their extensive research capabilities and established market presence. Roche (CH) focuses on developing targeted therapies, while Bristol-Myers Squibb (US) emphasizes immuno-oncology approaches that may extend to autoimmune conditions. Novartis (CH) is investing heavily in gene therapies, indicating a shift towards personalized medicine. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient-centric solutions.

In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain efficiency and reduce costs. The Pemphigus Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set trends in research and development, thereby shaping the overall market structure. The collective efforts of these key players suggest a trend towards consolidation, as smaller firms may seek partnerships or acquisitions to remain competitive.

In November 2025, Roche (CH) announced the initiation of a pivotal Phase III clinical trial for its novel monoclonal antibody targeting pemphigus vulgaris. This strategic move underscores Roche's commitment to advancing treatment options and potentially capturing a larger market share. The trial's success could significantly enhance Roche's portfolio, positioning it as a leader in the Pemphigus Market.

In October 2025, Bristol-Myers Squibb (US) entered into a collaboration with a biotech firm to co-develop a new immunotherapy for pemphigus. This partnership is indicative of a broader trend towards collaborative innovation, allowing both companies to pool resources and expertise. Such alliances may accelerate the development timeline and improve the therapeutic landscape for patients.

In September 2025, Novartis (CH) launched a digital health platform aimed at improving patient engagement and adherence to treatment regimens for pemphigus patients. This initiative reflects a growing emphasis on digital transformation within the healthcare sector, suggesting that companies are increasingly recognizing the importance of technology in enhancing patient outcomes.

As of December 2025, the competitive trends in the Pemphigus Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, as companies seek to enhance their capabilities and market reach. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift indicates a future where companies that prioritize research and development, alongside strategic partnerships, will likely emerge as leaders in the market.

Key Companies in the Pemphigus Market market include

Industry Developments

  • Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Market Vulgaris Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company.
  • Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Market Vulgaris Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel cell therapy candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris.
  • Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Market Vulgaris Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris.
  • Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Market Vulgaris Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions.
  • Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Market Programs Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris.
  • Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Market Vulgaris Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development.
  • Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris.
  • Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Market Vulgaris Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China.
  • Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Market Vulgaris Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results.
  • Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Market Clinical Programs Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris.

Global Pemphigus Market, by Pemphigus Market Types

  • Pemphigus Market Vulgaris
  • Pemphigus Market Foliaceus
  • Pemphigus Market Vegetans
  • Paraneoplastic Pemphigus Market

Global Pemphigus Market, by Diagnosis

  • Skin peeling
  • Skin biopsy
  • Run blood tests
  • Endoscopy

Global Pemphigus Market, by Treatment

  • Initial therapy
  • Maintenance therapy
  • Immunosuppressants
  • Biological therapies
  • Intravenous Immunoglobulin (IVIG) therapy
  • Other medication

Global Pemphigus Market, by End User

  • Laboratories
  • Hospitals and Clinics
  • Academic and Research Institutes

Global Pemphigus Market, by Region

  • Americas
  • North America
  • US
  • Canada
  • South America
  • Europe
  • Western Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Rest of Western Europe
  • Eastern Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Republic of Korea
  • Rest of Asia Pacific
  • Middle East & Africa
  • Middle East
  • Africa

Future Outlook

Pemphigus Market Future Outlook

<p>The Pemphigus Market is projected to grow at an 8.39% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing awareness, and rising patient populations.</p>

New opportunities lie in:

  • <p>Development of targeted biologic therapies for pemphigus vulgaris.</p>
  • <p>Expansion of telehealth services for <a href="https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905">remote patient monitoring</a></p>
  • <p>Investment in personalized medicine approaches for treatment optimization.</p>

<p>By 2035, the Pemphigus Market is expected to achieve substantial growth and innovation.</p>

Market Segmentation

Pemphigus Market Application Outlook

  • Dermatology
  • Oncology
  • Immunology
  • Transplantation

Pemphigus Market Treatment Type Outlook

  • Corticosteroids
  • Immunosuppressants
  • Biologics
  • Plasmapheresis

Pemphigus Market Type of Pemphigus Outlook

  • Pemphigus Vulgaris
  • Pemphigus Foliaceus
  • Paraneoplastic Pemphigus

Pemphigus Market Patient Demographics Outlook

  • Adults
  • Pediatric
  • Geriatric

Pemphigus Market Route of Administration Outlook

  • Oral
  • Intravenous
  • Subcutaneous

Report Scope

MARKET SIZE 2024 578.9(USD Million)
MARKET SIZE 2025 634.1(USD Million)
MARKET SIZE 2035 1410.37(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 8.39% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Amgen (US), Sanofi (FR), Merck & Co. (US), Pfizer (US), GSK (GB), Eli Lilly (US)
Segments Covered Application, Type of Pemphigus, Treatment Type, Route of Administration, Patient Demographics
Key Market Opportunities Advancements in biologics and targeted therapies enhance treatment options in the Pemphigus Market.
Key Market Dynamics Rising demand for targeted therapies drives innovation and competition in the Pemphigus treatment landscape.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is Pemphigus?

Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

What is the CAGR of the Pemphigus Market?

The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

What is the major driver for the Pemphigus Market?

The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

Which is the leading regional Pemphigus Market?

Americas are anticipated to dominate the global Pemphigus Market.

What are the leading Pemphigus Market players?

Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

  1. Definition
    1. Scope of the Study
      1. Research Objective
      2. Assumptions
      3. Limitations
    2. Introduction
    3. Primary Research
    4. Secondary Research
    5. Market Size Estimation
    6. Drivers
    7. Restraints
    8. Opportunities
    9. Challenges
    10. Macroeconomic Indicators
    11. Technology Trends & Assessment
    12. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
    13. Value Chain Analysis
    14. Investment Feasibility Analysis
    15. Pricing Analysis
  2. Chapter 6. Global Pemphigus Market, by Pemphigus Types
    1. Introduction
    2. Pemphigus Vulgaris
  3. Market Estimates & Forecast, by Region, 2020–2027
  4. Market Estimates & Forecast, by Country, 2020–2027
    1. Pemphigus Foliaceus
  5. Market Estimates & Forecast, by Region, 2020–2027
  6. Market Estimates & Forecast, by Country, 2020–2027
    1. Pemphigus Vegetans
  7. Market Estimates & Forecast, by Region, 2020–2027
  8. Market Estimates & Forecast, by Country, 2020–2027
    1. Paraneoplastic Pemphigus
  9. Market Estimates & Forecast, by Region, 2020–2027
  10. Market Estimates & Forecast, by Country, 2020–2027
  11. Chapter 7. Global Pemphigus Market, by Diagnosis
    1. Introduction
    2. Skin Peeling
  12. Market Estimates & Forecast, by Region, 2020–2027
  13. Market Estimates & Forecast, by Country, 2020–2027
    1. Skin Biopsy
  14. Market Estimates & Forecast, by Region, 2020–2027
  15. Market Estimates & Forecast, by Country, 2020–2027
    1. Run Blood Tests
  16. Market Estimates & Forecast, by Region, 2020–2027
  17. Market Estimates & Forecast, by Country, 2020–2027
    1. Endoscopy
  18. Market Estimates & Forecast, by Region, 2020–2027
  19. Market Estimates & Forecast, by Country, 2020–2027
  20. Chapter 8. Global Pemphigus Market, by Treatment
    1. Introduction
    2. Corticosteroids
  21. Market Estimates & Forecast, by Region, 2020–2027
  22. Market Estimates & Forecast, by Country, 2020–2027
    1. Initial Therapy
  23. Market Estimates & Forecast, by Region, 2020–2027
  24. Market Estimates & Forecast, by Country, 2020–2027
    1. Maintenance Therapy
  25. Market Estimates & Forecast, by Region, 2020–2027
  26. Market Estimates & Forecast, by Country, 2020–2027
    1. Immunosuppressants
  27. Market Estimates & Forecast, by Region, 2020–2027
  28. Market Estimates & Forecast, by Country, 2020–2027
    1. Biological Therapies
  29. Market Estimates & Forecast, by Region, 2020–2027
  30. Market Estimates & Forecast, by Country, 2020–2027
    1. Intravenous Immunoglobulin (IVIG) Therapy
  31. Market Estimates & Forecast, by Region, 2020–2027
  32. Market Estimates & Forecast, by Country, 2020–2027
    1. Other medication
  33. Market Estimates & Forecast, by Region, 2020–2027
  34. Market Estimates & Forecast, by Country, 2020–2027
  35. Chapter 9. Global Pemphigus Market, by End User
    1. Introduction
    2. Laboratories
  36. Market Estimates & Forecast, by Region, 2020–2027
  37. Market Estimates & Forecast, by Country, 2020–2027
    1. Hospitals and Clinics
  38. Market Estimates & Forecast, by Region, 2020–2027
  39. Market Estimates & Forecast, by Country, 2020–2027
    1. Academic and Research Institutes
  40. Market Estimates & Forecast, by Region, 2020–2027
  41. Market Estimates & Forecast, by Country, 2020–2027
  42. Chapter 10. Global Pemphigus Market, by Region
    1. Introduction
    2. Americas
      1. North America
      2. South America
    3. Europe
      1. Western Europe
      2. Eastern Europe
    4. Asia-Pacific
      1. Japan
      2. China
      3. India
      4. Australia
      5. South Korea
      6. Rest of Asia-Pacific
    5. Middle East & Africa
      1. Middle East
      2. Africa
    6. Chapter 11. Company Landscape
    7. Introduction
    8. Market Share Analysis
    9. Key Development & Strategies
    10. Chapter 12. Company Profiles
    11. Novartis Pharmaceuticals
      1. Company Overview
      2. Product Overview
      3. Financials Overview
      4. Key Developments
      5. SWOT Analysis
    12. Hoffmann-La Roche
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    13. Principia Biopharma, Inc
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    14. Argenx
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Development
      5. SWOT Analysis
    15. Sanofi S.A.
      1. Company Overview
      2. Product Overview
      3. Financial overview
      4. Key Developments
      5. SWOT Analysis
    16. Pfizer Inc
      1. Company Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    17. Teligent Inc
      1. Overview
      2. Product Overview
      3. Financial Overview
      4. Key Developments
      5. SWOT Analysis
    18. GlaxoSmithKline LLC
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    19. Teva Pharmaceutical Industries
      1. Overview
      2. Product Overview
      3. Financials
      4. Key Developments
      5. SWOT Analysis
    20. Chapter 13 MRFR Conclusion
    21. Key Findings
      1. From CEO’s Viewpoint
      2. Unmet Needs of the Market
    22. Key Companies to Watch
    23. Predictions for the Pemphigus Industry
    24. Chapter 14. Appendix
    25.  
  43. LIST OF TABLES
  44. Global Pemphigus Market Synopsis, 2020–2027
  45. Global Pemphigus Market Estimates and Forecast, 2020–2027
    1. (USD Million)
  46. Global Pemphigus Market, by Region, 2020–2027 (USD Million)
  47. Global Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
  48. Global Pemphigus Market, by Diagnosis, 2020–2027(USD Million)
  49. Global Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  50. Global Pemphigus Market, by End User, 2020–2027 (USD Million)
  51. North America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  52. North America: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  53. North America: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  54. North America: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  55. US: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
  56. US: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  57. US: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  58. US: Pemphigus Market, by End User, 2020–2027 (USD Million)
  59. Canada: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
  60. Canada: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  61. Canada: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  62. Canada: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  63. South America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  64. South America: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  65. South America: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  66. South America: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  67. Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
  68. Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  69. Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  70. Europe: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  71. Western Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  72. Western Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  73. Western Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  74. Western Europe: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  75. Eastern Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  76. Eastern Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  77. Eastern Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  78. Eastern Europe: Pemphigus Market, by End-User, 2020–2027(USD Million)
  79. Asia-Pacific: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD
    1. Million)
  80. Asia-Pacific: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
  81. Asia-Pacific: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  82. Asia-Pacific: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  83. Middle East & Africa: Pemphigus Market, by Pemphigus Types, 2020–2027
    1. (USD Million)
  84. Middle East & Africa: Pemphigus Market, by Technology, 2020–2027 (USD Million)
  85. Middle East & Africa: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
  86. Middle East & Africa: Pemphigus Market, by End-User, 2020–2027 (USD Million)
  87. LIST OF FIGURES
  88. Research Process
  89. Segmentation for Global Pemphigus Market
  90. Segmentation Market Dynamics for Global Pemphigus Market
  91. Global Pemphigus Market Share, By Pemphigus Types, 2020
  92. Global Pemphigus Market Share, By Diagnosis, 2020
  93. Global Pemphigus Market Share, By Treatment, 2020
  94. Global Pemphigus Market Share, By End User, 2020
  95. Global Pemphigus Market Share, By Region, 2020
  96. North America: Pemphigus Market Share, By Country, 2020
  97. Europe: Pemphigus Market Share, By Country, 2020
  98. Asia-Pacific: Pemphigus Market Share, By Country, 2020
  99. Middle East & Africa: Pemphigus Market Share, By Country, 2020
  100. Global Pemphigus Market: Company Share Analysis, 2020 (%)
  101. Novartis Pharmaceuticals.: Key Financials
  102. Novartis Pharmaceuticals.: Segmental Revenue
  103. Novartis Pharmaceuticals.: Geographical Revenue
  104. Hoffmann-La Roche.: Key Financials
  105. Hoffmann-La Roche.: Segmental Revenue
  106. Hoffmann-La Roche.: Geographical Revenue
  107. Principia Biopharma, Inc.: Key Financials
  108. Principia Biopharma, Inc.: Segmental Revenue
  109. Principia Biopharma, Inc.: Geographical Revenue
  110. Argenx: Key Financials
  111. Argenx: Segmental Revenue
  112. Argenx: Geographical Revenue
  113. Sanofi S.A.: Key Financials
  114. Sanofi S.A.: Segmental Revenue
  115. Sanofi S.A.: Geographical Revenue
  116. Pfizer Inc: Key Financials
  117. Pfizer Inc: Segmental Revenue
  118. Pfizer Inc: Geographical Revenue
  119. Teligent Inc: Key Financials
  120. Teligent Inc: Segmental Revenue
  121. Teligent Inc: Geographical Revenue
  122. GlaxoSmithKline LLC: Key Financials
  123. GlaxoSmithKline LLC: Segmental Revenue
  124. GlaxoSmithKline LLC: Geographical Revenue
  125. Teva Pharmaceutical Industries.: Key Financials
  126. Teva Pharmaceutical Industries.: Segmental Revenue
  127. Teva Pharmaceutical Industries.: Geographical Revenue

Pemphigus Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓